Tasgen Bio-Tech Co. Ltd.
Division of I-Mab Biopharma
Latest From Tasgen Bio-Tech Co. Ltd.
Genexine has reached a critical point in developing its immuno-oncology pipeline, firming up a $548m-plus licensing out pact for an asset with the Shanghai-based I-Mab Biopharma. The South Korean firm expects the deal to serve as a yardstick of ‘value determination’ in its future global transactions.
South Korean bioventure Genexine is on track to meet its goal of progressing and expanding this year the clinical development of its leading assets - orphan disease drugs and cancer immunotherapies. The company now plans to raise new funds via share and bond issues to domestic and overseas investors including its Chinese strategic alliance partner Tasly.
Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.